HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rose by over 8%, with record-high revenue and net profit last year, and the sales revenue of innovative drugs is expected to accelerate.

Jiangsu Hengrui Pharmaceuticals (01276) surged more than 8%, as of the time of writing, it has risen by 7.43%, to 65.8 Hong Kong dollars, with a turnover of 2.6 billion Hong Kong dollars. On the news front, recently, Jiangsu Hengrui Pharmaceuticals announced its performance for 2025, with revenue and net profit reaching new highs. The company achieved an operating income of 31.629 billion yuan for the whole year, an increase of 13.02% year-on-year; the net profit attributable to shareholders of the listed company was 7.711 billion yuan, an increase of 21.69% year-on-year. Sales revenue of innovative drugs reached 16.342 billion yuan, an increase of 26.09% year-on-year, accounting for 58.34% of drug sales revenue; external licensing income was 3.392 billion yuan, an increase of 25.62% year-on-year. According to a research report by Guotai Haitong, Jiangsu Hengrui Pharmaceuticals is expected to accelerate the growth of sales revenue of innovative drugs from 2026 onwards. Benefiting from the update of the medical insurance negotiation catalog at the end of 2025, the company will add 10 new drugs in 2026, as well as 5 existing products with new indications that will be included in the medical insurance reimbursement list, driving rapid growth in the company's innovative drug business in 2026.